Are New Drug Development Platforms Leading Pharma Innovation?

The European Pharmaceutical Manufacturer site noted that increasingly, the business model for drug discovery and development is predicated on recouping costs barely manageable for first-world, affluent nations. In an effort to combat this trend, various stakeholders in the drug discovery ecosystem have been identifying and exploring novel models based on collaboration and distribution of risk that provide new schemes for incentivizing and rewarding drug discovery. These business models can use curation markets and crowd-intelligence to discover valuable therapeutics and direct resources towards them. The overarching goal is to build incentives for a more open source R&D process that will bring down costs, accelerate development, bring more diverse treatments to market, and move stakeholders towards collaboration: new business models for the current broken pharma industry.

Click here to read an abstract of the article.

Image via Flickr.